AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03715634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
Trial: NCT00157105
Drug: Antihemophilic factor, recombinant, manufactured protein-free
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02312245
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02548585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously.
Trial: NCT00397098
Drug: SR58611A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00805441
Drug: LY686017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 milligrams (mg) daily by oral route for 12 weeks
Trial: NCT00805441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily by oral route for 12 weeks
Trial: NCT00141271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
Trial: NCT04917315
Drug: JLP-2002 A mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
Trial: NCT04917315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
Trial: NCT01720407
Drug: Placebo + surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
Trial: NCT02026583
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04321096
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00768716
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 500 mg by mouth once
Trial: NCT05361083
Drug: F18CETO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of F18CETO or O15water followed by PET/CT
Trial: NCT01391338
Drug: ASP3652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01391338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02717780
Drug: Fentanyl and sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02717780
Drug: Remifentanil and desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00547716
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00555620
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
Trial: NCT01289899
Drug: BR-A-657
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120, 360mg or placebo 7days
Trial: NCT02462720
Drug: Varithena®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varithena® treatment in accordance with full prescribing information and instructions for use
Trial: NCT02187120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00965393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic infusion of placebo (saline)
Trial: NCT01345253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
Trial: NCT01816165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
Trial: NCT01560962
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01560962
Drug: tobramycin-dexmethasone
RxNorm normalized name: dexamethasone / tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02454647
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00582855
Drug: AQW051
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00582855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03663049
Drug: discontinue statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue statin as prescribed for 12 weeks
Trial: NCT02331771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
Trial: NCT00003376
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003376
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01476137
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK inhibitor
Trial: NCT01476137
Drug: GSK2110183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKT inhibitor
Trial: NCT01684345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT00648271
Drug: Lopressor® Tablets 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x50mg, single dose fed
Trial: NCT00083148
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01809444
Drug: Prednisone+placebo of Doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
Trial: NCT01809444
Drug: Doxycycline+placebo of Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
Trial: NCT02199444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00202228
Drug: cofactor supplementation (thiamine, riboflavin, L-carnitine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
Trial: NCT03044756
Drug: Omit Citrotide 0.25 dose on the day of triggering of ovulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omit Citrotide 0.25 dose on the day of triggering of ovulation
Trial: NCT02069379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules prepared identically to Metformin capsules
Trial: NCT04113187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per os, twice a day (morning and evening) during three months
Trial: NCT00801905
Drug: Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
Trial: NCT00014508
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02869308
Drug: stannous pyrophosphate
RxNorm normalized name: Technetium (99m-Tc) stannous pyrophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 1ml Angiocis
Trial: NCT00561678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
Trial: NCT01862224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily (Week 0 to Week 12).
Trial: NCT01862224
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
Trial: NCT00330135
Drug: placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection - 1 injection
Trial: NCT00434642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
Trial: NCT00427544
Drug: PRA-027
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00244751
Drug: GI262570 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI262570 0.5 mg
Trial: NCT00244751
Drug: GI262570 1.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI262570 1.0 mg
Trial: NCT00244751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02785822
Drug: hMG-HP
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian stimulation with hMG-HP (150 IU / day)
Trial: NCT01879488
Drug: technetium-99m - Diethylenetriaminepentaacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00135226
Drug: Placebo Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01442766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
Trial: NCT01727193
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
Trial: NCT04325737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
Trial: NCT01375582
Drug: B & L Soothe Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Drop
Trial: NCT00882323
Drug: Cyclophosphamide, Fludarabine, Thymoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)
Trial: NCT02649478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02649478
Drug: Advair Diskus 100/50
RxNorm normalized name: Advair Diskus 100/50 Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
Trial: NCT04520620
Drug: Lovenox 40 MG in 0.4 mL Prefilled Syringe
RxNorm normalized name: Lovenox 40 MG in 0.4 mL Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with a high thrombotic risk:~In patients with a BMI included between \< 30 kg/m² and \> 30 kg/m² without added thrombotic risk factor:~* Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~* if weight \> 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI \> 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen \> 8 g/L or D-Dimer \> 3 μg/ml or 3000 ng/ml)~\* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours
Trial: NCT04035733
Drug: rVA576
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
Trial: NCT03022747
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 6-mercaptopurine and methotrexate
Trial: NCT01738087
Drug: NEXThaler 100/6 mcg DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00346242
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02954276
Drug: Imitrex Oral Product
RxNorm normalized name: Imitrex Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg
Trial: NCT01656512
Drug: zolendronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: patients will receive calcium \& vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~1. Initial dose: (0.025) mg /kg~2. Subsequent doses ( 0.05) mg /kg.~3. Maximum dose of 4 mg.
Trial: NCT01034774
Drug: ACHN-490 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
Trial: NCT00003996
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02420847
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00474409
Drug: Merislon
RxNorm normalized name: Merilog
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02108496
Drug: NSAID's and Non-surgical Treatment Options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
Trial: NCT02108496
Drug: Intra-Articular Injections with Corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
Trial: NCT01872260
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
Trial: NCT01225289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per day for six months
Trial: NCT02254122
Drug: BEA 2180 BR
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02254122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03430362
Drug: Hyoscine N Butylbromide
RxNorm normalized name: Hyoscine N butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
Trial: NCT03430362
Drug: Normal Saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B, will receive 2 ml of normal saline single intravenous dose
Trial: NCT01490047
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion over 60 minutes
Trial: NCT02619578
Drug: propofol, remifentanil, vecuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
Trial: NCT00021996
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01177644
Drug: PDS 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03063983
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous oral cyclophosphamide
Trial: NCT03063983
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous oral methotrexate
Trial: NCT00515879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same dosage as active pill
Trial: NCT03537534
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applying surgilube following endourologic procedure
Trial: NCT03586284
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 to 28 days of placebo pill treatment
Trial: NCT03586284
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 to 28 days of topical placebo treatment
Trial: NCT01612507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 h infusion
Trial: NCT01612507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 h infusion
Trial: NCT00006220
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04057300
Drug: acetylsalicylic acid (ASA) 81mg
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylsalicylic acid tablet
Trial: NCT03062488
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multi-modal analgesia with IV acetaminophen
Trial: NCT03062488
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single modal analgesia
Trial: NCT03062488
Drug: PO acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multi-modal analgesia with PO acetaminophen
Trial: NCT00972686
Drug: GSK2126458
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2126458 is an experimental treatment for patients with cancer.
Trial: NCT01404702
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg/m2/dose given iv on day 0 of every 28 day cycle
Trial: NCT00324363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection twice daily in volumes equal to exenatide
Trial: NCT02227888
Drug: N91115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S nitrosoglutathione reductase inhibitor
Trial: NCT00215943
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
Trial: NCT03332589
Drug: E6201
RxNorm normalized name: TRACH STOMA PROTECTOR,CLOTH WHITE BE6201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6201 formulated in cyclodextrin for IV administration.
Trial: NCT03624023
Drug: TWB-103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
Trial: NCT01563445
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
Trial: NCT04232085
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GVHD prophylaxis
Trial: NCT01252199
Drug: cαStx1/cαStx2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
Trial: NCT01252199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered over 1 hour + standard of care
Trial: NCT01025648
Drug: E004 (epinephrine inhalation aerosol), 125 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
Trial: NCT01025648
Drug: E004 (epinephrine inhalation aerosol), 220 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period